DELFI

OSF HealthCare and DELFI Diagnostics Announce Collaboration to Improve Lung Cancer Screening Rates

Retrieved on: 
월요일, 5월 13, 2024
Patient, DNA, OSF HealthCare, Ministry, NPV, Elevated railway, Lung cancer, Disease, Health, DELFI, Blood, Cancer, OSF, Standard of care, PALO, Medical imaging

PEORIA, Ill. and PALO ALTO, Calif., May 13, 2024 /PRNewswire/ -- OSF HealthCare, a 16-hospital integrated health system that serves patients in Illinois and Michigan, and DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced a collaboration to utilize DELFI's FirstLook Lung blood-based cancer screening test to help improve screening rates. DELFI's collaboration with OSF was recently highlighted by the Biden Cancer Moonshot to expand accessibility to lung cancer screening.

Key Points: 
  • PEORIA, Ill. and PALO ALTO, Calif., May 13, 2024 /PRNewswire/ -- OSF HealthCare , a 16-hospital integrated health system that serves patients in Illinois and Michigan, and DELFI Diagnostics, Inc ., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced a collaboration to utilize DELFI's FirstLook Lung blood-based cancer screening test to help improve screening rates.
  • DELFI's collaboration with OSF was recently highlighted by the Biden Cancer Moonshot to expand accessibility to lung cancer screening.
  • Lung cancer is the leading cause of cancer deaths both domestically and globally, and studies show that proactive annual screening can reduce death rates by 20% or more.
  • "Early detection of lung cancer is key to improving patient outcomes, and we are confident that innovative, accessible new screening approaches like FirstLook Lung will move the needle on lung cancer screening rates among our patients," said James McGee, MD, radiation oncologist and founding director of the OSF HealthCare Cancer Institute.

Frank Elderson: “Know thyself” – avoiding policy mistakes in light of the prevailing climate science

Retrieved on: 
목요일, 4월 18, 2024
European Convention, Reproduction, Failure, European Court, Face, Human rights, Frankfurt, Climate, United Nations, World Bank Group, Investment, Paris Agreement, International economics, Policy, Bank of Greece, Wildfire, Speech, Environment, United Nations Environment Programme, Science, ECB, Blog, Risk, Education, EIOPA, Communication, Drought, Ancient Greek, Climate change, Safety, Watcher, De Nederlandsche Bank, Procrastination, Depression, European Environment Agency, Green, Tourism, Knowledge, Research, Food, Private sector, Insurance, IPCC, Movement, European Central Bank, The, Temperature, Health, Uncertainty, Attention, Conference, Financial system, Supervisory board, Oracle, Bank, Fishery, Flood, Thought, DELFI, Water, World Bank, Persians, Government, International human rights law, Renewable energy

Stock market development and familiarity (language and distance) are considered key determinants for home bias.

Key Points: 
  • Stock market development and familiarity (language and distance) are considered key determinants for home bias.
  • The literature neglects however that investors often invest in foreign funds domiciled in financial centers.

DELFI Diagnostics to Present at American Association for Cancer Research Annual Meeting

Retrieved on: 
월요일, 4월 1, 2024
Lung cancer, Poster, DELFI, AACR, PALO, Cancer, Patient, Medical imaging

PALO ALTO, Calif. and BALTIMORE, April 1, 2024 /PRNewswire/ -- DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced multiple upcoming poster and oral presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego, California, from April 5-10, 2024. DELFI and independent researchers will highlight the performance of the company's next-generation, fragmentomics-based liquid biopsy platform to help detect early cancer and monitor treatment response.

Key Points: 
  • New data further validate FirstLook Lung cancer screening test, highlight the broad potential of DELFI's fragmentomic-based approach in early cancer detection and treatment monitoring
    PALO ALTO, Calif. and BALTIMORE, April 1, 2024 /PRNewswire/ -- DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced multiple upcoming poster and oral presentations at the American Association for Cancer Research (AACR) Annual Meeting , taking place in San Diego, California, from April 5-10, 2024.
  • DELFI and independent researchers will highlight the performance of the company's next-generation, fragmentomics-based liquid biopsy platform to help detect early cancer and monitor treatment response.
  • "DELFI's robust presence at AACR this year reflects our substantial clinical progress in demonstrating the DELFI platform's high performance in a range of applications across multiple tumor types," said Susan Tousi, DELFI Chief Executive Officer.
  • Patients need better cancer screening and treatment-monitoring options, while health systems and payers need affordable and broadly accessible tests that improve patient outcomes.

How Artificial Intelligence Could Trigger a Natural Gas Boom in Europe

Retrieved on: 
화요일, 3월 5, 2024
Cloud, BP, Neuron, Bed, ExxonMobil, Shell, GOOGL, Machine learning, Big, Software, Fracture, Google Cloud, Amazon Web Services, Eye, MSFT, SOM, Self-organizing map, AMZN, Porosity, Cloud computing, Microsoft, Environment, AWS, Partnership, Amazon (company), DELFI, Azure, Convolutional neural network, MCF, IBM Watson, IBM, Safety, Alphabet Inc., CNN, Machine, Artificial intelligence, Human, AI, Data management, Geology, Risk, Schlumberger, Paradise, Deep learning, Video game

LONDON, March 5, 2024 /PRNewswire/ -- When the use of seismic surveys became commonplace, Oil and gas drillers used to drill only in spots the human eye could detect from seismic and other data, but that's all changing now. The next round of onshore discoveries is being aided by new Artificial Intelligence and Machine Learning software that sees what we can't, forever disrupting the exploration game. Companies mentioned in this release include: Alphabet Inc. (NASDAQ:GOOGL), Amazon.com, Inc. (NASDAQ:AMZN), C3.ai, Inc. (NYSE:AI), Microsoft Corporation (NASDAQ:MSFT), International Business Machines Corporation (NYSE:IBM).

Key Points: 
  • The next round of onshore discoveries is being aided by new Artificial Intelligence and Machine Learning software that sees what we can't, forever disrupting the exploration game.
  • MCF saw the value of this technology early on and has used it extensively wherever possible in their search for gas in Europe, according to its CEO, James Hill.
  • Mordor Intelligence projected oil and gas spending on AI to close out 2023 at $2.38 billion, and to reach $4.21 billion by the end of 2028.
  • And strategic partnerships with companies like Chevron and Schlumberger are fueling the digital transformation of the oil and gas sector.

How Artificial Intelligence Could Trigger a Natural Gas Boom in Europe

Retrieved on: 
화요일, 3월 5, 2024
Cloud, BP, Neuron, Bed, ExxonMobil, Shell, GOOGL, Machine learning, Big, Software, Fracture, Google Cloud, Amazon Web Services, Eye, MSFT, SOM, Self-organizing map, AMZN, Porosity, Cloud computing, Microsoft, Environment, AWS, Partnership, Amazon (company), DELFI, Azure, Convolutional neural network, MCF, IBM Watson, IBM, Safety, Alphabet Inc., CNN, Machine, Artificial intelligence, Human, AI, Data management, Geology, Risk, Schlumberger, Paradise, Deep learning, Video game

LONDON, March 5, 2024 /PRNewswire/ -- When the use of seismic surveys became commonplace, Oil and gas drillers used to drill only in spots the human eye could detect from seismic and other data, but that's all changing now. The next round of onshore discoveries is being aided by new Artificial Intelligence and Machine Learning software that sees what we can't, forever disrupting the exploration game. Companies mentioned in this release include: Alphabet Inc. (NASDAQ:GOOGL), Amazon.com, Inc. (NASDAQ:AMZN), C3.ai, Inc. (NYSE:AI), Microsoft Corporation (NASDAQ:MSFT), International Business Machines Corporation (NYSE:IBM).

Key Points: 
  • The next round of onshore discoveries is being aided by new Artificial Intelligence and Machine Learning software that sees what we can't, forever disrupting the exploration game.
  • MCF saw the value of this technology early on and has used it extensively wherever possible in their search for gas in Europe, according to its CEO, James Hill.
  • Mordor Intelligence projected oil and gas spending on AI to close out 2023 at $2.38 billion, and to reach $4.21 billion by the end of 2028.
  • And strategic partnerships with companies like Chevron and Schlumberger are fueling the digital transformation of the oil and gas sector.

DELFI Diagnostics Announces Availability of New Fragmentome-Based Cancer Treatment Monitoring Assay

Retrieved on: 
목요일, 2월 1, 2024
Liquid biopsy, MAF, Immunocore, Research, Clonal hematopoiesis, PALO, Patient, DELFI, TCR, ImmTAC, RUO, Neoplasm, Cancer, Plasma, Nucleic acid thermodynamics

PALO ALTO, Calif. and BALTIMORE, Feb. 1, 2024 /PRNewswire/ -- DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced availability of the company's fragmentome-based research use only (RUO) cancer monitoring assay. The DELFI-Tumor Fraction (DELFI-TF) assay is a highly sensitive, inexpensive means of noninvasive measurement of tumor burden and assessing treatment response and resistance in patients with advanced cancer.

Key Points: 
  • PALO ALTO, Calif. and BALTIMORE, Feb. 1, 2024 /PRNewswire/ -- DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced availability of the company's fragmentome-based research use only (RUO) cancer monitoring assay.
  • The DELFI-Tumor Fraction (DELFI-TF) assay is a highly sensitive, inexpensive means of noninvasive measurement of tumor burden and assessing treatment response and resistance in patients with advanced cancer.
  • Additionally, DELFI announced a new research collaboration with Immunocore Holdings plc (Nasdaq: IMCR) – a commercial-stage biotechnology company pioneering the development of a novel class of bispecific T cell receptor (TCR) immunotherapies against cancer (ImmTAC molecules) – focused on exploring the use of the DELFI-TF cancer monitoring assay as an early predictor of benefit from treatment with ImmTAC-based therapies.
  • "We are excited that Immunocore will be further exploring the clinical and research potential of the DELFI liquid biopsy platform as a new approach to monitoring treatment response."

DELFI Diagnostics Appoints Susan Tousi as New Chief Executive Officer

Retrieved on: 
금요일, 1월 5, 2024
University, Geography, DELFI, Mechanics, Woman, Software, Research, NAE, Acquisition, Lung cancer, Disease, Pennsylvania State University, MBA, Cancer, Kodak, National academy, Genomics, PALO, Engineering, IVD, Informatics, Patient, Corporation, Hewlett-Packard, Euronext, Management

BALTIMORE and PALO ALTO, Calif., Jan. 5, 2024 /PRNewswire/ -- DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced the appointment of Susan Tousi as Chief Executive Officer. Ms. Tousi joins DELFI from Illumina, Inc. where she held multiple leadership roles during a more than 10-year tenure, most recently as Chief Commercial Officer leading global sales, service and support, commercial operations and strategy.

Key Points: 
  • Ms. Tousi joins DELFI from Illumina, Inc. where she held multiple leadership roles during a more than 10-year tenure, most recently as Chief Commercial Officer leading global sales, service and support, commercial operations and strategy.
  • We are excited to welcome her to the team," said Liz Homans, DELFI Board Chair and former CEO of Lyell Immunopharma.
  • "Susan is behind the engineering and launch of several of Illumina's most impactful, globally profitable products.
  • This translatable expertise makes her the right fit to drive DELFI forward and lead the commercial strategy for the FirstLook Lung liquid biopsy test."

DELFI Diagnostics Supports Proposed Legislation to Allow CMS to Review New Blood-Based Screening Tests for Lung Cancer

Retrieved on: 
수요일, 12월 13, 2023
Liquid biopsy, Food and Drug Administration, Social, Woman, PALO, Food, Congress.gov, DELFI, Representative, Social Security, Mortality, Agency, XVIII, House, Death, FDA, Social Security Act, Steel, USPSTF, CMS, Lung cancer, Medicare, Congress, Louisiana House of Representatives, NCD, Prevent Cancer Foundation, Legislation, Public, Mobile phone, Dietary supplement

CMS currently lacks the authority to cover additional approaches to lung cancer screening, such as blood-based ("liquid biopsy") tests, even though access to more screening options may improve lung cancer screening rates.

Key Points: 
  • CMS currently lacks the authority to cover additional approaches to lung cancer screening, such as blood-based ("liquid biopsy") tests, even though access to more screening options may improve lung cancer screening rates.
  • If passed, this bill would enable CMS to use its national coverage determination (NCD) authority and existing coverage standards to review new lung cancer screening tests as well, expediting reviews of products that would enhance the existing lung cancer screening pathway."
  • The Lung Cancer Screening and Prevention Act would amend title XVIII of the Social Security Act to provide this authority, but does not mandate that CMS either review or cover any new lung cancer screening tests in the Medicare program.
  • The proposed legislation aligns with U.S. President Biden's Cancer Moonshot initiative focused on expanding equitable access to cancer screening and prevention, and could be a catalyst both to increasing lung cancer screening and lowering lung cancer mortality rates – key objectives of Healthy People 2030 .

DELFI Diagnostics Launches FirstLook Lung, an Accessible, Accurate New Way to Enhance Lung Cancer Screening Through a Routine Blood Test

Retrieved on: 
월요일, 10월 9, 2023
Diagnosis, Health, Cancer, Lung cancer, Machine learning, DNA, Disease, Lung, Patient, DELFI, CT, MIT Tech Talk, Science, Nucleic acid thermodynamics, NPV, PDT, New Way, Blood, Liquid biopsy, National Lung Screening Trial, PALO, National Cancer Institute, Medical imaging

BALTIMORE and PALO ALTO, Calif., Oct. 9, 2023 /PRNewswire/ -- DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, announced today the initial commercial introduction of FirstLook Lung. FirstLook is a blood test that offers a convenient, accurate and personalized result by determining the likelihood of detecting lung cancer through low-dose CT (LDCT), with a negative predictive value (NPV) of 99.7 percent.

Key Points: 
  • FirstLook Lung uses these millions of data points to reliably identify individuals who may have lung cancer, including early-stage disease.
  • With high sensitivity, including for early-stage disease, FirstLook Lung identifies the majority of people who will have lung cancer identified by LDCT.
  • FirstLook's 99.7 percent NPV means that individuals who do not show signs of lung cancer are not likely to have lung cancer found by LDCT.
  • "We started with lung cancer because the shortfall in screening for this disease is the largest unmet need in cancer early detection today.

DELFI Diagnostics to Highlight Breakthrough Technology and Completed Clinical Study in Lung Cancer Detection

Retrieved on: 
수요일, 10월 4, 2023
DNA, Cleveland Clinic, Nucleic acid thermodynamics, PALO, HST, Liquid biopsy, Cancer, Lung cancer, PDT, Science, New Way, Machine learning, Annual general meeting, Cleveland, MPH, MIT Tech Talk, Medical imaging, Mobile phone, DELFI

BALTIMORE and PALO ALTO, Calif., Oct. 4, 2023 /PRNewswire/ -- DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to detect cancer, announced today that the company will participate in multiple sessions at the HLTH 2023 conference in Las Vegas, Nevada, and the CHEST 2023 Annual Meeting in Honolulu, Hawai'i, both taking place October 8-11, 2023.

Key Points: 
  • DELFI's approach to early cancer detection applies advanced machine learning technology to whole-genome sequencing data to compare an individual's cell-free DNA (cfDNA) patterns and characteristics against populations with and without cancer.
  • An oral presentation at CHEST will highlight new data from the DELFI-L101 Study, "DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study," a prospective, multicenter, case-control study among individuals eligible for lung cancer screening to train and independently validate the blood-based test for early cancer detection.
  • Victor Velculescu, M.D., Ph.D., DELFI Founder and Chief Executive Officer, will deliver a science and technology presentation on the company's lung cancer early detection test.
  • As part of the "Updates in Lung Cancer" session, Peter Mazzone, M.D., MPH, Director of the Lung Cancer Program and Lung Cancer Screening Program for the Respiratory Institute at the Cleveland Clinic and the principal investigator for DELFI's L101 study, will present new data from the study during an oral presentation.